Leptin aggravates house dust mite-induced airway inflammation by accelerating macrophage necroptosis

Tiantian Liu1, Yuying Huang1, Liang Zhang2

  • 1Department of Traditional Chinese Medicine, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

PubMed
Abstract

Insights

Leptin worsens asthma by promoting macrophage necroptosis, a cell death pathway. Targeting leptin or necroptosis could offer new asthma treatments.

Area of Science:

  • Immunology
  • Cell Biology
  • Respiratory Medicine

Background:

  • Leptin, a pro-inflammatory adipokine, is linked to asthma.
  • Macrophage necroptosis, a form of programmed cell death, is implicated in airway inflammation.

Purpose of the Study:

  • To investigate if leptin exacerbates asthma by mediating macrophage necroptosis.
  • To elucidate the role of leptin in regulating macrophage necroptosis during asthma development.

Main Methods:

  • Established a house dust mite (HDM)-induced asthma model in mice using leptin deficiency, leptin administration, and high-fat diet (HFD).
  • Assessed airway inflammation, hyperresponsiveness (AHR), and performed RNA-sequencing on alveolar macrophages (AMs).
  • Utilized in vivo macrophage depletion and in vitro cell experiments to confirm mechanisms.

Main Results:

  • Leptin deficiency alleviated HDM-induced airway inflammation and AHR, while leptin supplementation and HFD worsened them.
  • Leptin was found to be involved in the necroptosis signaling pathway, upregulating key necroptosis markers (p-RIPK3, p-MLKL) and inflammation in lung tissue and macrophages.
  • Leptin enhanced macrophage apoptosis and IL-6 secretion, and AM depletion reversed leptin deletion's protective effects.

Conclusions:

  • Leptin exacerbates HDM-induced airway inflammation by enhancing macrophage necroptosis.
  • Targeting the leptin-macrophage necroptosis axis presents a potential therapeutic strategy for asthma intervention.

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
453
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.0K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
573
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K